Vaderis Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$152M
- Investors
-
8
Vaderis Therapeutics General Information
Description
Developer of oral medicine designed for the treatment of rare and orphan diseases caused by vascular malformations. The company's medicine can treat the symptoms of hereditary hemorrhagic telangiectasia (HHT) and reduce the occurrence of new lesions, enabling doctors to modify the progression of HHT.
Contact Information
Website
www.vaderis.comCorporate Office
- WSJ-350 3.05, Lichtstrasse 35
- 4056 Basel
- Switzerland
Corporate Office
- WSJ-350 3.05, Lichtstrasse 35
- 4056 Basel
- Switzerland
Vaderis Therapeutics Timeline
Vaderis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 11-Aug-2026 | $152M | Completed | Clinical Trials - Phase 1 | ||
| 2. Early Stage VC | 02-Oct-2023 | Completed | Clinical Trials - Phase 1 | |||
| 1. Early Stage VC (Series A) | 01-May-2020 | $18.5M | $18.5M | Completed | Clinical Trials - Phase 1 |
Vaderis Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-3 | ||||||||
| Series A-2 | ||||||||
| Series A | 15,338,983 | $0.011110 | $0.47 | $0.47 | 1x | $0.47 | 37.76% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Vaderis Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Vaderis Therapeutics Patents
Vaderis Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021352108-A1 | Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia | Active | 30-Sep-2020 | ||
| AU-2021352108-A9 | Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia | Active | 30-Sep-2020 | ||
| AU-2021352108-B2 | Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia | Active | 30-Sep-2020 | ||
| CA-3192433-A1 | Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia | Pending | 30-Sep-2020 | ||
| EP-4221713-A1 | Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia | Pending | 30-Sep-2020 | A61K31/5383 |
Vaderis Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Vaderis Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| EQT Life Sciences | Venture Capital | Minority | ||
| Goldman Sachs Asset Management | Asset Manager | Minority | ||
| Kalehua Capital Management | PE/Buyout | Minority | ||
| Omega Funds | Venture Capital | Minority | ||
| Perceptive Advisors | Venture Capital | Minority |
Vaderis Therapeutics Investments (1)
Vaderis Therapeutics’s most recent deal was a Corporate Asset Purchase with Almac Discovery (Allosteric AKT Inhibitors). The deal was made on 01-Apr-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Almac Discovery (Allosteric AKT Inhibitors) | 01-Apr-2020 | Corporate Asset Purchase | Buildings and Property |
Vaderis Therapeutics FAQs
-
When was Vaderis Therapeutics founded?
Vaderis Therapeutics was founded in 2019.
-
Where is Vaderis Therapeutics headquartered?
Vaderis Therapeutics is headquartered in Basel, Switzerland.
-
What is the size of Vaderis Therapeutics?
Vaderis Therapeutics has 20 total employees.
-
What industry is Vaderis Therapeutics in?
Vaderis Therapeutics’s primary industry is Drug Discovery.
-
Is Vaderis Therapeutics a private or public company?
Vaderis Therapeutics is a Private company.
-
What is Vaderis Therapeutics’s current revenue?
The current revenue for Vaderis Therapeutics is .
-
How much funding has Vaderis Therapeutics raised over time?
Vaderis Therapeutics has raised $194M.
-
Who are Vaderis Therapeutics’s investors?
EQT Life Sciences, Goldman Sachs Asset Management, Kalehua Capital Management, Omega Funds, and Perceptive Advisors are 5 of 8 investors who have invested in Vaderis Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
